Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AZD 1222

Drug Profile

AZD 1222

Alternative Names: AZD-1222; ChAdOx1 nCoV-19; ChAdOx1 nCoV-19-vaccine; ChAdOx1-nCoV-19-vaccine-Barinthus Biotherapeutics/University-of-Oxford; chadox1-s; COVID-19 vaccine - AstraZeneca; COVID-19 vaccine - Barinthus Biotherapeutics/University of Oxford; Covishield; SII-ChAdOx1 nCoV-19; Vaxzevria; VTP-900

Latest Information Update: 15 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Oxford; Vaccitech
  • Developer AstraZeneca; Gamaleya Research Institute of Epidemiology and Microbiology; R-Pharm; University of Oxford
  • Class COVID-19 vaccines; Synthetic vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - COVID 2019 infections

Highest Development Phases

  • Marketed COVID 2019 infections

Most Recent Events

  • 27 Mar 2024 Astrazeneca withdraws marketing authorization application from EMA for AZD 1222 in COVID-2019 infections
  • 27 Mar 2024 Withdrawn for COVID-2019 infections (In the elderly, Prevention, In adults) in France (IM)
  • 27 Mar 2024 Withdrawn for COVID-2019 infections (In the elderly, Prevention, In adults) in Poland (IM)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top